Investigating hemophagocytosis in critically ill adults
Official title: Hemophagocytosis in Critically Ill Adult Patients With Cytopenias
Run by University of Ulm · NCT01913938 · Data updated 2026-11-12
This study is trying to see if critically ill adults with low blood cell counts and signs of a serious condition called hemophagocytic lymphohistiocytosis respond to a specific treatment to help improve their situation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of Ulm Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Ulm and 1 other locations) |
| Status | Recruiting |
| Started | July 2013 |
| Main results expected | July 2025 |
| Study ends | December 2026 |
| Registry record updated | January 17, 2024 |
| Trial ID | NCT01913938 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are critically ill adults over 18 years old with leukopenia and thrombocytopenia receiving rhG-CSF therapy.
✕Probably not a fit
Patients with a life expectancy of less than 24 hours, those involved in other studies, or those with certain hematologic disorders or malignancies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to determine the relationship between non-responsiveness to recombinant human granulocyte colony-stimulation factor (rhG-CSF) and hemophagocytosis in critically ill adult patients experiencing cytopenias. It focuses on whether adults with bicytopenia or pancytopenia who meet clinical criteria for hemophagocytic lymphohistiocytosis (HLH) exhibit life-threatening hemophagocytosis. The study will analyze the responsiveness to rhG-CSF therapy in these patients to better understand the condition's implications.
Why it matters
Potential benefit: If successful, this study could improve the understanding and management of hemophagocytosis in critically ill adults, potentially leading to better treatment strategies.
How similar studies have gone: While hemophagocytosis has been studied primarily in children, this approach in adults is less explored, making it a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \> 18 years * critically ill adult patients * leukopenia and thrombocytopenia * rhG-CSF therapy Exclusion Criteria: * life expectancy \< 24 hours * inclusion in other studies * trauma patients with reanimation on scene or immediately dying on hospital admission * pregnancy * hematologic disorder, malignancy * high dose corticosteroid treatment or chemotherapy
Where it's running
-
Department of Anaesthesiology, University Hospital Ulm
Ulm, Germany Recruiting -
Department of Internal Medicine III, Comprehensive Infectious Disease Center, University Hospital Ulm, Germany
Ulm, Germany Recruiting
Study contacts
- Principal investigator: Manfred E Weiss, MD — Department of Anesthesiology
- Study coordinator: Manfred E Weiss, MD
- Email: manfred.weiss@uniklinik-ulm.de
- Phone: 49-731-50060226
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.